What do systematic reviews say?

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.56 [0.24, 10.05]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.23 [0.35, 4.4]
  2 studies · 144 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 66 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 76 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 110 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 110 participants
  Moderate

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in mortality Mortality at latest compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.75, 1.49]
  3 studies · 413 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in acute rejection The number of patients who experienced at least one… compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.89 [0.77, 1.05]
  2 studies · 323 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus probably leads to lower bronchiolitis obliterans syndrome The number of patients diagnosed… compared with cyclosporin (moderate certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.46 [0.29, 0.74]
  3 studies · 413 participants
  Moderate

Tacrolimus vs cyclosporin

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to lower treatment withdrawal the number of patients stopping the assigned… compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.27 [0.16, 0.46]
  3 studies · 413 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to lower arterial hypertension compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 0.67 [0.5, 0.89]
  2 studies · 164 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus may leads to higher diabetes mellitus compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 4.24 [1.58, 11.4]
  2 studies · 164 participants
  Low